Vantage logo

Are we there yet?

Second-quarter share price movements give another glimpse of the dire state of the markets, but there might be reasons for optimism.

Vantage logo

The Cytomx paradox

Failure of the company’s in-house lead raises questions about the viability of its extensively partnered probody technology.